AU2007287098C1 - Methods and compositions for treating cancer - Google Patents

Methods and compositions for treating cancer Download PDF

Info

Publication number
AU2007287098C1
AU2007287098C1 AU2007287098A AU2007287098A AU2007287098C1 AU 2007287098 C1 AU2007287098 C1 AU 2007287098C1 AU 2007287098 A AU2007287098 A AU 2007287098A AU 2007287098 A AU2007287098 A AU 2007287098A AU 2007287098 C1 AU2007287098 C1 AU 2007287098C1
Authority
AU
Australia
Prior art keywords
day
therapeutically effective
effective amount
abiraterone acetate
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007287098A
Other languages
English (en)
Other versions
AU2007287098A1 (en
AU2007287098B2 (en
Inventor
Alan H. Auerbach
Arie S. Belldegrun
Johann S. de Bono
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38916904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2007287098(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2007287098A1 publication Critical patent/AU2007287098A1/en
Publication of AU2007287098B2 publication Critical patent/AU2007287098B2/en
Application granted granted Critical
Assigned to JANSSEN ONCOLOGY, INC. reassignment JANSSEN ONCOLOGY, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: COUGAR BIOTECHNOLOGY, INC.
Priority to AU2015221447A priority Critical patent/AU2015221447B9/en
Priority to AU2017201764A priority patent/AU2017201764A1/en
Publication of AU2007287098C1 publication Critical patent/AU2007287098C1/en
Assigned to JANSSEN PHARMACEUTICA NV reassignment JANSSEN PHARMACEUTICA NV Request for Assignment Assignors: JANSSEN ONCOLOGY, INC.
Priority to AU2018271331A priority patent/AU2018271331A1/en
Priority to AU2021201649A priority patent/AU2021201649A1/en
Priority to AU2022206696A priority patent/AU2022206696A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2007287098A 2006-08-25 2007-08-23 Methods and compositions for treating cancer Active AU2007287098C1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2015221447A AU2015221447B9 (en) 2006-08-25 2015-08-31 Methods and compositions for treating cancer
AU2017201764A AU2017201764A1 (en) 2006-08-25 2017-03-15 Methods and compositions for treating cancer
AU2018271331A AU2018271331A1 (en) 2006-08-25 2018-11-29 Methods and compositions for treating cancer
AU2021201649A AU2021201649A1 (en) 2006-08-25 2021-03-16 Methods and compositions for treating cancer
AU2022206696A AU2022206696A1 (en) 2006-08-25 2022-07-18 Methods and compositions for treating cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92150606P 2006-08-25 2006-08-25
US60/921,506 2006-08-25
PCT/US2007/018769 WO2008024484A1 (en) 2006-08-25 2007-08-23 Methods and compositions for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015221447A Division AU2015221447B9 (en) 2006-08-25 2015-08-31 Methods and compositions for treating cancer

Publications (3)

Publication Number Publication Date
AU2007287098A1 AU2007287098A1 (en) 2008-02-28
AU2007287098B2 AU2007287098B2 (en) 2013-08-15
AU2007287098C1 true AU2007287098C1 (en) 2018-03-15

Family

ID=38916904

Family Applications (6)

Application Number Title Priority Date Filing Date
AU2007287098A Active AU2007287098C1 (en) 2006-08-25 2007-08-23 Methods and compositions for treating cancer
AU2015221447A Ceased AU2015221447B9 (en) 2006-08-25 2015-08-31 Methods and compositions for treating cancer
AU2017201764A Abandoned AU2017201764A1 (en) 2006-08-25 2017-03-15 Methods and compositions for treating cancer
AU2018271331A Abandoned AU2018271331A1 (en) 2006-08-25 2018-11-29 Methods and compositions for treating cancer
AU2021201649A Ceased AU2021201649A1 (en) 2006-08-25 2021-03-16 Methods and compositions for treating cancer
AU2022206696A Abandoned AU2022206696A1 (en) 2006-08-25 2022-07-18 Methods and compositions for treating cancer

Family Applications After (5)

Application Number Title Priority Date Filing Date
AU2015221447A Ceased AU2015221447B9 (en) 2006-08-25 2015-08-31 Methods and compositions for treating cancer
AU2017201764A Abandoned AU2017201764A1 (en) 2006-08-25 2017-03-15 Methods and compositions for treating cancer
AU2018271331A Abandoned AU2018271331A1 (en) 2006-08-25 2018-11-29 Methods and compositions for treating cancer
AU2021201649A Ceased AU2021201649A1 (en) 2006-08-25 2021-03-16 Methods and compositions for treating cancer
AU2022206696A Abandoned AU2022206696A1 (en) 2006-08-25 2022-07-18 Methods and compositions for treating cancer

Country Status (20)

Country Link
EP (3) EP2061561B1 (enExample)
JP (10) JP2010501575A (enExample)
KR (4) KR20180003636A (enExample)
CN (2) CN101528308A (enExample)
AU (6) AU2007287098C1 (enExample)
CA (1) CA2661422C (enExample)
CY (2) CY1115477T1 (enExample)
DK (2) DK2478907T3 (enExample)
ES (2) ES2869343T3 (enExample)
HR (2) HRP20130961T1 (enExample)
HU (1) HUE054495T2 (enExample)
IL (3) IL197211A0 (enExample)
LT (1) LT2478907T (enExample)
NO (2) NO20091190L (enExample)
NZ (1) NZ597830A (enExample)
PL (2) PL2478907T3 (enExample)
PT (2) PT2478907T (enExample)
RS (2) RS62034B1 (enExample)
SI (2) SI2478907T1 (enExample)
WO (1) WO2008024484A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62034B1 (sr) 2006-08-25 2021-07-30 Janssen Oncology Inc Kompozicije za lečenje raka
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
WO2009009132A1 (en) * 2007-07-12 2009-01-15 Cougar Biotechnology, Inc. Use of 17alpha-hydroxylase/c17, 20-lyase inhibitors for the treatment of cancer
RU2481107C2 (ru) * 2007-10-29 2013-05-10 Такеда Фармасьютикал Компани Лимитед Средство для профилактики или лечения рака
CN102558274B (zh) * 2010-12-08 2014-10-15 深圳万乐药业有限公司 一种适合工业化生产醋酸阿比特龙的合成方法
CN102558275A (zh) * 2010-12-20 2012-07-11 天津药物研究院 α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物
MX356704B (es) 2011-01-11 2018-06-11 Novartis Ag Combinación.
CA2831922C (en) 2011-04-01 2019-12-31 Genentech, Inc. Combinations of akt inhibitor compounds and vemurafenib, and methods of use
US20120295932A1 (en) * 2011-05-17 2012-11-22 Western Connecticut Health Network, Inc. Method for the treatment of cancer
CN103070828B (zh) * 2011-10-26 2016-01-27 山东新时代药业有限公司 一种含醋酸阿比特龙的固体分散体、片剂及其制备方法
CN102336801B (zh) * 2011-10-31 2013-05-15 南京卡文迪许生物工程技术有限公司 醋酸阿比特龙多晶型物和药用组合物
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
WO2013184621A1 (en) * 2012-06-06 2013-12-12 Novartis Ag Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
PT3305285T (pt) 2012-09-26 2020-11-24 Aragon Pharmaceuticals Inc Antiandrogénios para o tratamento de cancro da próstata resistente à castração não metastático
CN103800296A (zh) * 2012-11-13 2014-05-21 重庆医药工业研究院有限责任公司 一种稳定的阿比特龙口服固体药物组合物及其制备方法
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
CN105246598B (zh) * 2013-03-15 2019-09-13 太阳药业环球公司 乙酸阿比特龙酯制剂
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
AU2014248001A1 (en) * 2013-04-04 2015-11-19 Exelixis, Inc. Drug combinations to treat cancer
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
US20160235714A1 (en) * 2013-10-01 2016-08-18 Novartis Ag Enzalutamide in combination with afuresertib for the treatment of cancer
EP3718544A1 (en) * 2013-10-01 2020-10-07 Novartis AG Combination
CN104546745A (zh) * 2013-10-14 2015-04-29 深圳海王药业有限公司 醋酸阿比特龙的片剂组合物及其制备工艺
EP3280448B1 (en) 2015-04-10 2020-12-30 Capsugel Belgium NV Abiraterone acetate lipid formulations
WO2018023017A1 (en) 2016-07-29 2018-02-01 Janssen Pharmaceutica Nv Methods of treating prostate cancer
JOP20190244A1 (ar) * 2017-04-13 2019-10-13 Janssen Pharmaceutica Nv تركيبة علاجية لسرطان البروستاتا
EP4438126A3 (en) 2017-10-16 2025-01-01 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CN109718198A (zh) * 2017-10-30 2019-05-07 浙江京新药业股份有限公司 一种治疗前列腺癌的注射剂及其制备方法
DK3935068T3 (da) * 2019-03-06 2023-12-04 Propella Therapeutics Inc Abirateron-prodrugs
WO2021031991A1 (zh) * 2019-08-16 2021-02-25 中国科学院分子细胞科学卓越创新中心 治疗激素依赖性疾病及减少激素依赖性疾病患者药物耐受的组合物和方法
US20230158047A1 (en) * 2020-04-16 2023-05-25 Tavanta Therapeutics Hungary Incorporated Methods and compositions for treating prostate cancer
CN114560903B (zh) * 2022-03-09 2023-08-01 绍兴市上虞区武汉理工大学高等研究院 一种阿比特龙衍生物的制备方法及其细胞毒性评价
LU506495B1 (en) 2024-03-01 2025-09-01 Alfasan Nederland B V 17alpha-HYDROXYLASE/17,20-LYASE (CYP17A1) INHIBITORS FOR THE TREATMENT OF SPONTANEOUS HYPERADRENOCORTICISM IN DOGS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053138A2 (en) * 2001-01-02 2002-07-11 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
WO2004037269A1 (en) * 2002-10-23 2004-05-06 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
US20060030608A1 (en) * 2004-08-04 2006-02-09 Boehringer Ingelheim Pharmaceuticals, Inc. Anti aromatase compounds pharmaceutical compositions and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69327096T2 (de) 1992-03-31 2000-06-21 Btg International Ltd., London 17-substituierte steroide, verwendbar bei behandlung von krebs
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
ES2300323T3 (es) * 2000-03-02 2008-06-16 Univ Pittsburgh Quimioterapia combinada.
WO2004062620A2 (en) * 2003-01-13 2004-07-29 Cedars-Sinai Medical Center Paricalcitol as a chemotherapeutic agent
GB0418900D0 (en) * 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
RS62034B1 (sr) 2006-08-25 2021-07-30 Janssen Oncology Inc Kompozicije za lečenje raka

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053138A2 (en) * 2001-01-02 2002-07-11 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
WO2004037269A1 (en) * 2002-10-23 2004-05-06 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
US20060030608A1 (en) * 2004-08-04 2006-02-09 Boehringer Ingelheim Pharmaceuticals, Inc. Anti aromatase compounds pharmaceutical compositions and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
O'DONNELL A ET AL, BRITISH JOURNAL OF CANCER VOL 90, NO 12, 14 JUNE 2004, PAGES 2317-2325 *

Also Published As

Publication number Publication date
JP2017052791A (ja) 2017-03-16
ES2869343T3 (es) 2021-10-25
HRP20210670T1 (hr) 2021-06-11
SI2061561T1 (sl) 2013-11-29
CN104306977A (zh) 2015-01-28
EP3804730A1 (en) 2021-04-14
EP2061561A1 (en) 2009-05-27
AU2017201764A1 (en) 2017-04-06
JP2010501575A (ja) 2010-01-21
JP2020114851A (ja) 2020-07-30
AU2015221447B9 (en) 2017-07-20
JP6740497B2 (ja) 2020-08-12
HK1131577A1 (en) 2010-01-29
CY1124221T1 (el) 2022-05-27
AU2022206696A1 (en) 2022-08-11
KR20150108946A (ko) 2015-09-30
AU2015221447B2 (en) 2016-12-15
KR20090059126A (ko) 2009-06-10
KR20200125776A (ko) 2020-11-04
JP2021038252A (ja) 2021-03-11
EP2478907A2 (en) 2012-07-25
NO20200775A1 (no) 2009-03-20
CN101528308A (zh) 2009-09-09
SI2478907T1 (sl) 2021-08-31
CA2661422A1 (en) 2008-02-28
JP2012082215A (ja) 2012-04-26
PL2061561T3 (pl) 2013-12-31
AU2018271331A1 (en) 2018-12-20
PL2478907T3 (pl) 2021-10-25
IL227746A0 (en) 2013-09-30
RS62034B1 (sr) 2021-07-30
JP6445123B2 (ja) 2018-12-26
DK2478907T3 (da) 2021-05-25
AU2007287098A1 (en) 2008-02-28
JP2019059750A (ja) 2019-04-18
JP2024164147A (ja) 2024-11-26
HUE054495T2 (hu) 2021-09-28
JP2022185091A (ja) 2022-12-13
KR20180003636A (ko) 2018-01-09
ES2428634T3 (es) 2013-11-08
AU2021201649A1 (en) 2021-04-08
EP2061561B1 (en) 2013-07-10
HRP20130961T1 (hr) 2013-11-22
DK2061561T3 (da) 2013-10-07
IL197211A0 (en) 2009-12-24
EP2478907B1 (en) 2021-04-14
LT2478907T (lt) 2021-06-25
EP2478907A3 (en) 2012-08-01
PT2478907T (pt) 2021-05-26
CY1115477T1 (el) 2017-01-04
AU2007287098B2 (en) 2013-08-15
JP2018065859A (ja) 2018-04-26
JP6053279B2 (ja) 2016-12-27
WO2008024484A1 (en) 2008-02-28
RS52956B (sr) 2014-02-28
NO20091190L (no) 2009-03-20
JP2015110577A (ja) 2015-06-18
NZ597830A (en) 2013-02-22
PT2061561E (pt) 2013-10-09
AU2015221447A1 (en) 2015-09-17
IL257681A (en) 2018-04-30
CA2661422C (en) 2017-06-27

Similar Documents

Publication Publication Date Title
AU2007287098C1 (en) Methods and compositions for treating cancer
US10702540B2 (en) Methods and compositions for treating cancer
US20110319369A1 (en) Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent
WO2008024485A2 (en) Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent
US20110021470A1 (en) Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
HK1173966A (en) Compositions for treating cancer

Legal Events

Date Code Title Description
CB Opposition filed

Opponent name: NORTHERN RIVERS PTY LTD

ON Decision of a delegate or deputy of the commissioner of patents (result of patent office hearing)

Free format text: (2015) APO 53: DECISION: I ALLOW THE AMENDMENT TO THE STATEMENT OF GROUNDS AND PARTICULARS. THE OPPOSITION FAILS ON ALL GROUNDS. I AWARD COSTS ACCORDING TO SCHEDULE 8 AGAINST NORTHERN RIVERS PTY LTD. SUBJECT TO APPEAL, I DIRECT THAT THE APPLICATION PROCEED TO GRANT.

Opponent name: NORTHERN RIVERS PTY LTD

Effective date: 20150819

FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 30 AUG 2017

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ AUERBACH, ALAN H.; BELLDEGRUN, ARIE S. AND DE BONO, JOHANN S.

TH Corrigenda

Free format text: IN VOL 31 , NO 49 , PAGE(S) 7091 UNDER THE HEADING AMENDMENTS - APPLICATION FOR AMENDMENTS UNDER THE NAME JANSSEN ONCOLOGY, INC., APPLICATION NO. 2007287098 CORRECT THE DATE OF THE STATEMENTS FILED TO READ 30 AUG 2017, 24 OCT 2017 AND 24 NOV 2017

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 30 AUG 2017; 24 OCT 2017 AND 24 NOV 2017

PC Assignment registered

Owner name: JANSSEN PHARMACEUTICA NV

Free format text: FORMER OWNER(S): JANSSEN ONCOLOGY, INC.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ AUERBACH, ALAN H.; BELLDEGRUN, ARIE S. AND DE BONO, JOHANN S.